RGN-259
Scope
Date
~
-
Korean stock market
Record $259 bn yet to find investment targets in South Korea
South Koreans parked a record 350 trillion won ($259 billion) in cash-equivalents such as money market funds (MMFs) as they failed to find investmen...
May 16, 2024 (Gmt+09:00)
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand